ONO PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,276 JPY | -1.04% |
|
-0.72% | -9.54% |
| 09:41am | Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion | RE |
| 29/04 | US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week | MT |
Valuation
| Fiscal Period: Maart | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 11,15,128 | 12,40,811 | 14,42,521 | 15,12,876 | 13,49,755 | 10,69,073 | - | - |
| Enterprise Value (EV) 1 | 10,45,860 | 11,79,553 | 13,78,498 | 14,43,704 | 12,53,600 | 9,11,896 | 8,48,767 | 8,04,690 |
| P/E ratio | 21.6 x | 21 x | 19.1 x | 18.9 x | 12 x | 8.28 x | 9.64 x | 9.04 x |
| Yield | 2.07% | 1.81% | 1.73% | 1.83% | 2.53% | 3.51% | 3.56% | 3.62% |
| Capitalization / Revenue | 3.86 x | 4.24 x | 4.66 x | 4.19 x | 3.02 x | 2.1 x | 2.21 x | 2.13 x |
| EV / Revenue | 3.62 x | 4.03 x | 4.46 x | 4 x | 2.8 x | 1.79 x | 1.75 x | 1.6 x |
| EV / EBITDA | 14.4 x | 12.9 x | 12.1 x | 11.9 x | 7.86 x | 4.79 x | 5.26 x | 4.72 x |
| EV / FCF | 61.5 x | 17.7 x | 84.1 x | 21.3 x | 8.64 x | 7.29 x | 7.62 x | 6.98 x |
| FCF Yield | 1.63% | 5.65% | 1.19% | 4.7% | 11.6% | 13.7% | 13.1% | 14.3% |
| Price to Book | 2 x | 2.21 x | 2.27 x | 2.28 x | 1.82 x | 1.35 x | 1.24 x | 1.14 x |
| Nbr of stocks (in thousands) | 5,14,121 | 4,99,120 | 4,99,142 | 4,93,436 | 4,88,334 | 4,69,716 | - | - |
| Reference price 2 | 2,169 | 2,486 | 2,890 | 3,066 | 2,764 | 2,276 | 2,276 | 2,276 |
| Announcement Date | 09/05/19 | 12/05/20 | 11/05/21 | 11/05/22 | 10/05/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,88,634 | 2,92,420 | 3,09,284 | 3,61,361 | 4,47,187 | 5,08,476 | 4,84,235 | 5,03,000 |
| EBITDA 1 | 72,631 | 91,705 | 1,14,150 | 1,20,916 | 1,59,414 | 1,90,570 | 1,61,297 | 1,70,422 |
| EBIT 1 | 62,010 | 77,491 | 98,330 | 1,03,195 | 1,41,963 | 1,72,228 | 1,45,786 | 1,54,529 |
| Operating Margin | 21.48% | 26.5% | 31.79% | 28.56% | 31.75% | 33.87% | 30.11% | 30.72% |
| Earnings before Tax (EBT) 1 | 65,141 | 79,696 | 1,00,890 | 1,05,025 | 1,43,532 | 1,74,250 | 1,46,223 | 1,56,073 |
| Net income 1 | 51,539 | 59,704 | 75,425 | 80,519 | 1,12,723 | 1,31,879 | 1,12,465 | 1,19,160 |
| Net margin | 17.86% | 20.42% | 24.39% | 22.28% | 25.21% | 25.94% | 23.23% | 23.69% |
| EPS 2 | 100.2 | 118.5 | 151.1 | 162.2 | 230.8 | 274.9 | 236.1 | 251.9 |
| Free Cash Flow 1 | 17,011 | 66,682 | 16,391 | 67,867 | 1,45,113 | 1,25,172 | 1,11,393 | 1,15,292 |
| FCF margin | 5.89% | 22.8% | 5.3% | 18.78% | 32.45% | 24.62% | 23% | 22.92% |
| FCF Conversion (EBITDA) | 23.42% | 72.71% | 14.36% | 56.13% | 91.03% | 65.68% | 69.06% | 67.65% |
| FCF Conversion (Net income) | 33.01% | 111.69% | 21.73% | 84.29% | 128.73% | 94.91% | 99.05% | 96.75% |
| Dividend per Share 2 | 45.00 | 45.00 | 50.00 | 56.00 | 70.00 | 79.92 | 81.00 | 82.36 |
| Announcement Date | 09/05/19 | 12/05/20 | 11/05/21 | 11/05/22 | 10/05/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,49,008 | 1,43,412 | 1,50,474 | - | 86,714 | 1,74,077 | 97,353 | 89,931 | 1,06,722 | 1,09,979 | 2,16,701 | 1,22,319 | 1,08,167 | 1,20,016 | 1,38,697 | 2,58,713 | 1,31,190 | 1,23,574 | 1,14,880 | - | 2,34,593 | - | - |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 51,933 | 51,450 | - | - | - | - | - |
| EBIT 1 | 41,878 | 35,613 | 52,401 | - | 28,379 | 58,171 | 23,996 | 21,028 | 38,162 | 42,108 | 80,270 | 42,320 | 19,373 | 41,348 | 55,688 | 97,036 | 47,590 | 31,005 | 36,146 | - | 73,306 | - | - |
| Operating Margin | 28.1% | 24.83% | 34.82% | - | 32.73% | 33.42% | 24.65% | 23.38% | 35.76% | 38.29% | 37.04% | 34.6% | 17.91% | 34.45% | 40.15% | 37.51% | 36.28% | 25.09% | 31.46% | - | 31.25% | - | - |
| Earnings before Tax (EBT) 1 | 43,042 | 36,654 | 53,674 | - | 28,427 | 59,231 | 25,118 | 20,676 | 39,041 | 41,978 | 81,019 | 43,360 | 19,153 | 42,378 | 56,918 | 99,296 | 47,996 | 24,254 | 36,531 | - | 74,076 | - | - |
| Net income 1 | 32,816 | 26,888 | 39,849 | - | 22,216 | 46,290 | 18,330 | 15,899 | 29,477 | 32,862 | 62,339 | 33,317 | 17,067 | 31,818 | 42,673 | 74,491 | 36,053 | 25,519 | 27,738 | - | 56,247 | - | - |
| Net margin | 22.02% | 18.75% | 26.48% | - | 25.62% | 26.59% | 18.83% | 17.68% | 27.62% | 29.88% | 28.77% | 27.24% | 15.78% | 26.51% | 30.77% | 28.79% | 27.48% | 20.65% | 24.15% | - | 23.98% | - | - |
| EPS 2 | 64.58 | - | 79.84 | - | 44.51 | 92.74 | 36.87 | 32.58 | 60.37 | 67.30 | 127.7 | 68.23 | 34.95 | 65.16 | 88.17 | 153.3 | 75.75 | 51.98 | 59.70 | - | 121.2 | - | - |
| Dividend per Share 2 | 22.50 | - | 22.50 | 27.50 | - | 28.00 | - | - | - | - | 33.00 | - | - | - | 40.00 | 40.00 | - | 40.00 | - | 45.00 | - | - | 45.00 |
| Announcement Date | 31/10/19 | 12/05/20 | 29/10/20 | 11/05/21 | 01/11/21 | 01/11/21 | 31/01/22 | 11/05/22 | 01/08/22 | 31/10/22 | 31/10/22 | 31/01/23 | 10/05/23 | 31/07/23 | 01/11/23 | 01/11/23 | 31/01/24 | - | - | - | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 69,268 | 61,258 | 64,023 | 69,172 | 96,155 | 1,57,176 | 2,20,306 | 2,64,382 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 17,011 | 66,682 | 16,391 | 67,867 | 1,45,113 | 1,25,172 | 1,11,393 | 1,15,292 |
| ROE (net income / shareholders' equity) | 9.5% | 10.7% | 12.6% | 12.5% | 16.1% | 17.2% | 13.4% | 13.1% |
| ROA (Net income/ Total Assets) | 10.3% | 12% | 14.2% | 14.1% | 17.7% | 15.6% | 12.2% | 12.1% |
| Assets 1 | 5,00,145 | 4,97,621 | 5,30,900 | 5,69,650 | 6,36,778 | 8,47,632 | 9,22,563 | 9,80,860 |
| Book Value Per Share 2 | 1,084 | 1,127 | 1,273 | 1,343 | 1,519 | 1,688 | 1,842 | 2,005 |
| Cash Flow per Share 2 | 121.0 | 147.0 | 183.0 | 198.0 | 267.0 | 259.0 | 274.0 | 302.0 |
| Capex 1 | 22,303 | 7,475 | 7,018 | 5,497 | 14,497 | 22,750 | 22,583 | 22,543 |
| Capex / Sales | 7.73% | 2.56% | 2.27% | 1.52% | 3.24% | 4.47% | 4.66% | 4.48% |
| Announcement Date | 09/05/19 | 12/05/20 | 11/05/21 | 11/05/22 | 10/05/23 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
2,276
JPY
Average target price
2,714
JPY
Spread / Average Target
+19.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.54% | 6.9B | |
| +19.27% | 43.75B | |
| +27.47% | 22.06B | |
| +15.11% | 14.46B | |
| +12.33% | 13.62B | |
| +38.36% | 11.61B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +9.64% | 5.32B | |
| -2.27% | 4.8B |
- Stock Market
- Equities
- 4528 Stock
- Financials Ono Pharmaceutical Co., Ltd.
